Approved for use through 07/31/2006, OMS 0851-0931 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/597,559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	December 7, 2006		
				First Named Inventor	Emi Sumida		
				Art Unit	N/A		
(out as many sinces as necessary)				Examiner Name	N/A		
Sheet	1	of	1	Attorney Docket Number	20080-00005		

	7 64.	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	Ishihara et at. "Hemocompatibility of human whole blood on polymers with a phospholipids polar group and its mechanism" Journal of Biomedical Materials Research, Vol. 26, 1543-1552 (1992).			
	C2	ishthara et al. "Selective adhesion of ptatelets on a potyton complex composed of phospholipids polymers containing sulfonate groups and quarternary ammonium groups" Journal of Stomedical Materials Research, Vol. 28, 12347-1355 (1994).			
	C3	Kassolis et al. "Alveolar Ridge and Sinus Augmentation Utilizing Platelet-Rich Plasma in Combination with Freeze-Dried bone Allograft: Case Series" Journal of Periodontology, Vol. 71, No. 10, October 2000.			
•••••	C4	Sanchez et al. 'Is Platelet-Rich Plasma the Perfect Enhancement Factor? A Current Review* International Journal of Oral and Maxillofacial Implants, Vol. 18, No. 1, 2002, pages 93-103.			
······	C5	Man et al. "The Use of Autologous Platelet-Rich Plasma (Platelet Get) and Autologous Platelet-Poor Plasma (Fibrin Glue) in Cosmetic Surgery" Plastic and Reconstructive Surgery, Vol. 107, No. 1, January 2001 (2001-01) pages 229-235.	•••••		
	C6	Sumida et al. "Platelet separation from whole blood in an aqueous two-phase system with water-soluble polymers" Journal of Pharmacological Sciences May 2006, Vol. 101, No. 1, May 2006, pages 91-97.			
	C7	Kwiatkowska, J. "Mechanism of erythrocyte agglomeration and sedimentation in polymer solutions and plasma" POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, Vol. 25, No. 6, 1971, pages 831-878.			

Examiner	Date	
Signature	Considered	

[&]quot;EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique challon destination number (optional). 2 Applicant is to place a check mark rate if English language Translation is adactive.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO).

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This coflection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.